股权激励
Search documents
大地海洋: 杭州大地海洋环保股份有限公司2024年限制性股票激励计划(草案修订稿)摘要
Zheng Quan Zhi Xing· 2025-08-22 16:49
Core Points - The company has proposed a 2024 Restricted Stock Incentive Plan aimed at enhancing corporate governance and aligning the interests of shareholders and management [1][6][10] - The plan involves granting a total of 2.34 million restricted shares, representing 2.15% of the company's total share capital of 108.92 million shares [2][12] - The grant price for the restricted shares is set at 9.52 RMB per share, which is below the average trading price prior to the announcement [17][18] - The plan is designed to attract and retain key management talent, ensuring alignment with the company's long-term development goals [6][23] Summary by Sections Purpose and Principles - The plan aims to establish a robust incentive mechanism to ensure the company's strategic goals are met while safeguarding shareholder interests [6][10] - It emphasizes the alignment of interests among shareholders, the company, and its management [6] Management Structure - The highest authority for the plan is the shareholders' meeting, which will approve the plan and any changes [7] - The board of directors is responsible for executing the plan, with oversight from the supervisory board [8] Incentive Objects - The plan targets three individuals: the board members and senior management, excluding independent directors and supervisors [9][12] - The selection of incentive objects is based on legal and performance criteria [9] Stock Source and Distribution - The restricted shares will be sourced from the company's repurchase from the secondary market or through targeted issuance [2][12] - The distribution of shares among the incentive objects is equal, with each receiving 78,000 shares [12] Validity and Granting Conditions - The plan is valid for a maximum of 48 months from the date of grant [13] - The granting of shares is contingent upon the approval of the shareholders' meeting and must occur within 60 days of approval [14] Vesting Arrangements - Shares will vest in three phases based on performance and tenure, with specific performance targets set for each phase [15][19] - The performance targets include net profit growth rates, with varying thresholds for each vesting period [19][23] Adjustment Mechanisms - The plan includes provisions for adjusting the number and price of shares in response to corporate actions such as stock splits or dividends [24][25] Accounting Treatment - The company will account for the stock options according to relevant accounting standards, estimating the fair value of the shares at the time of grant [26][27] - The estimated impact on net profit due to the stock option expenses is expected to be minimal compared to the potential positive effects on company performance [28] Handling Changes in Company or Incentive Objects - The plan will terminate if the company faces significant adverse events, with unvested shares being forfeited [29] - Changes in the status of incentive objects, such as job changes, will affect their eligibility for unvested shares [29]
岱勒新材: 关于2021年限制性股票激励计划预留授予部分第二个归属期归属条件成就的公告
Zheng Quan Zhi Xing· 2025-08-22 16:48
Core Viewpoint - The company has announced the achievement of the second vesting conditions for its stock incentive plan, allowing for the vesting of 982,800 shares of restricted stock to eligible participants [1][13][21] Summary by Sections Stock Incentive Plan Overview - The stock incentive plan was initiated with a total of 87 million shares, with 8.12% allocated for the initial grant and 18.69% reserved for future grants [1][2] - The first grant consisted of 8.7 million shares, representing 81.31% of the total incentive plan [1] Vesting Conditions and Performance Targets - The vesting schedule includes three periods: 40% after 12 months, 30% after 24 months, and 30% after 36 months from the initial grant date [2][3] - The performance targets for the first vesting period require a net profit of 30 million yuan or a revenue increase of 30% for 2022 [3][4] - For the second vesting period, the targets are set at a net profit of 60 million yuan or a revenue increase of 60% for 2023 [4][5] Approval and Compliance - The board of directors and the supervisory board have approved the vesting conditions, confirming that the conditions have been met for the eligible participants [13][17] - The company has followed necessary procedures and disclosed information in compliance with relevant regulations [18][20] Impact on Financials - The vesting of 982,800 shares will increase the total share capital, potentially affecting earnings per share and return on equity [21] - The company does not anticipate significant impacts on its financial condition or operational results from this vesting [21]
华大智造: 2024年限制性股票激励计划(草案修订稿)摘要公告
Zheng Quan Zhi Xing· 2025-08-22 16:48
Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].
华大智造: 2024年限制性股票激励计划(草案修订稿)
Zheng Quan Zhi Xing· 2025-08-22 16:48
Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. is implementing a restricted stock incentive plan for 2024, aiming to attract and retain talent while aligning the interests of shareholders, the company, and employees [1][2]. Group 1: Incentive Plan Overview - The incentive plan involves granting 6.555 million restricted stocks, accounting for 1.58% of the company's total share capital of 415.6376 million shares [2][3]. - The grant price for the restricted stocks is set at 26.15 RMB per share [2][7]. - The plan will be effective for a maximum of 36 months from the date of stock grant [3][15]. Group 2: Eligibility and Conditions - A total of 325 employees, including directors, senior management, core technical personnel, and key business staff, are eligible for the incentive plan [3][12]. - The plan stipulates that the restricted stocks will not confer shareholder rights until they are vested, and they cannot be transferred or used as collateral before vesting [2][3]. - The vesting of stocks is contingent upon meeting both company-level performance targets and individual performance assessments [3][21]. Group 3: Performance Assessment - The performance assessment for the company will be based on revenue growth excluding impacts from public health events, with a baseline revenue of 2.709 billion RMB for 2023 [21][25]. - The performance targets for the first and second vesting periods will be evaluated based on the growth rates of revenue and sales of sequencing instruments [22][23]. - Individual performance will also be assessed, with ratings determining the actual number of shares vested [24][25]. Group 4: Management and Oversight - The plan will be managed by the board of directors, with a compensation and assessment committee responsible for drafting and revising the plan [10][11]. - The supervisory board will oversee the implementation of the plan, ensuring it aligns with the company's long-term development and does not harm shareholder interests [10][11]. - The plan requires approval from the shareholders' meeting before implementation [10][31]. Group 5: Adjustments and Accounting - Adjustments to the number of restricted stocks and their grant price may occur due to corporate actions such as stock splits or capital increases [29][30]. - The accounting treatment for the restricted stocks will follow relevant accounting standards, with costs recognized over the vesting period [30][31].
乐普医疗: 关于变更回购股份用途并注销暨减少注册资本、修订公司章程的公告
Zheng Quan Zhi Xing· 2025-08-22 16:36
Core Viewpoint - The company plans to change the purpose of repurchased shares from "employee stock ownership plan" to "reduce registered capital" and will seek shareholder approval for the cancellation of these shares [5][8]. Summary by Sections 1. Share Repurchase Plan Overview - In 2021, the company approved a share repurchase plan to buy back shares for employee stock ownership, with a maximum price of RMB 35 per share and a total fund of between RMB 30 million and RMB 50 million [1][2]. - By November 1, 2022, the company repurchased 18,273,500 shares, accounting for 0.9653% of the total share capital, with a total expenditure of RMB 355.78 million [2]. 2. Changes in Repurchase Plan - The company decided to terminate the 2022 restricted stock incentive plan due to unmet performance targets and stock price fluctuations [3]. - In 2023, a new repurchase plan was approved with a maximum price of RMB 25 per share and a total fund of between RMB 25 million and RMB 50 million [4]. 3. Change of Purpose for Repurchased Shares - The company intends to change the purpose of 37,215,700 repurchased shares to reduce registered capital, which will require shareholder approval [5][8]. - After the cancellation, the total share capital will decrease from 1,880,611,391 shares to 1,843,395,691 shares [5][7]. 4. Impact of Share Cancellation - The cancellation of repurchased shares is expected to enhance financial metrics such as earnings per share and net asset value without adversely affecting the company's operations or shareholder interests [8]. 5. Approval Process - The board of directors and the supervisory board have both approved the proposal to change the purpose of the repurchased shares and will seek shareholder approval for the necessary amendments to the company's articles of association [9].
海通发展: 福建海通发展股份有限公司董事会薪酬与考核委员会对公司2023、2024、2025年股权激励计划相关事项的核查意见
Zheng Quan Zhi Xing· 2025-08-22 16:36
Group 1 - The company plans to repurchase and cancel 302,600 restricted stocks and 164,000 stock options due to one incentive object failing to meet personal performance assessments in the 2023 and 2025 incentive plans [1][2] - The first exercise conditions for the 2024 stock option and restricted stock incentive plan have been met, allowing 13 incentive objects to exercise a total of 345,000 stock options [2] - The second unlock condition for the 2023 restricted stock incentive plan has been achieved, allowing 38 incentive objects to unlock and circulate 1,336,440 restricted stocks, which accounts for 0.14% of the company's total share capital [3]
万东医疗: 万东医疗第十届董事会第十次会议决议公告
Zheng Quan Zhi Xing· 2025-08-22 16:36
Core Viewpoint - The company held its 10th board meeting on August 22, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and plans for stock options and share repurchase [1][2][3]. Group 1: Meeting Resolutions - The board approved the 2025 semi-annual report and summary, which was recognized by the audit committee prior to submission [1]. - A special report on the status of the company's fundraising and actual usage was also approved, following the audit committee's review [2]. - The board approved a proposal to grant reserved stock options to the incentive objects of the 2025 stock option incentive plan, which had been reviewed by independent directors and relevant committees [2]. - The board approved a share repurchase plan using self-owned funds through centralized bidding, aimed at enhancing the long-term incentive mechanism and employee motivation [2].
罗莱生活: 关于注销部分股票期权的公告
Zheng Quan Zhi Xing· 2025-08-22 16:24
Core Viewpoint - The company has approved the cancellation of 1.255 million stock options granted to 9 departing incentive recipients, which will not impact the company's operational performance or management diligence [1][4]. Summary by Sections Stock Incentive Plan Overview - The company held meetings to discuss and approve the stock incentive plan, including the cancellation of stock options for departing employees [1][2]. Cancellation Reasons and Quantity - The cancellation involves 1.255 million stock options due to the departure of 9 incentive recipients who no longer qualify for the incentive program [4]. Impact of Cancellation on the Company - The cancellation of stock options will not affect the company's operational performance or the diligence of the management team [4]. Supervisory Board Opinion - The supervisory board confirmed that the cancellation process complies with relevant regulations and the company's incentive plan, deeming it legal and effective [4]. Legal Opinions - The legal firm provided an opinion stating that the cancellation of stock options has received necessary approvals and complies with relevant laws and regulations, affirming that it will not impact the company's performance [4].
罗莱生活: 关于回购注销部分限制性股票的公告
Zheng Quan Zhi Xing· 2025-08-22 16:24
证券代码:002293 证券简称:罗莱生活 公告编号:2025-035 罗莱生活科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏。 罗莱生活科技股份有限公司(以下简称"公司"或"罗莱生活")于2025 年8月21日召开了第六届董事会第十五次会议与第六届监事会第十三次会议,审 议通过了《关于回购注销部分限制性股票的议案》,同意对2名离职的激励对象 已获授但尚未解除限售的25万股限制性股票予以回购注销,该议案尚需提交公司 一、股权激励计划简述 《关于 <公司 ensp="ensp" 年限制性股票与股票期权激励计划="年限制性股票与股票期权激励计划" 草案 ="草案"> 及其摘要的议案》 《关于 <公司 ensp="ensp" 年限制性股票与股票期权激励计划实施考核管理办法="年限制性股票与股票 期权激励计划实施考核管理办法"> 的议案》 及《关于核实公司<2024 年限制性股票与股票期权激励计划首次授予激励对象名 单>的议案》,同意公司实施本次激励计划。 票期权激励计划首次授予激励对象名单,对本次拟激励对象姓名及职务予以公示, 公示时间为 2024 ...
恒生电子: 恒生电子股份有限公司监事会关于2022年股票期权激励计划第三个行权期行权条件未成就及注销部分已授予股票期权的核查意见
Zheng Quan Zhi Xing· 2025-08-22 14:18
恒生电子股份有限公司 恒生电子股份有限公司 监事会关于公司 2022 年股票期权激励计划第三个行权期行权条件未 成就及注销部分已授予股票期权的核查意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 股权激励管理办法》等法律、法规以及《恒生电子股份有限公司章程》的规定, 恒生电子股份有限公司(以下简称"公司")监事会就公司2022年股票期权激励 计划(以下简称"激励计划")第三个行权期行权条件未成就及注销部分已授予 股票期权事项进行了核查,发表意见如下: 一、根据激励计划规定的行权条件,公司 2024 年业绩未达到激励计划规定的 公司层面业绩考核条件,公司 2022 年股票期权激励计划第三个行权期行权条件 未成就,该行权期激励对象对应考核当年可行权的股票期权不得行权,均由公司 注销。该行权期拟注销的股份数量为 633.848 万份。 二、鉴于原激励对象中 5 人因离职或职务变更而不再具备激励对象资格,监 事会同意取消上述激励对象资格并注销其已获授但尚未行权的股票期权合计 公司拟注销因上述原因不得行权的股票期权合计 646.6547 万份。本次注销 符合《上市公司股权激励管理办法》《2022 ...